Gastroenterology
Volume 127, Issue 6 , Pages 1704-1713, December 2004

Serum markers detect the presence of liver fibrosis: A cohort study

  • William M.C. Rosenberg

      Affiliations

    • Liver Group, Division of Infection, Inflammation and Repair, University of Southampton, Southampton, England
    • Corresponding Author InformationAddress requests for reprints to: William M. C. Rosenberg, DPhil, FRCP, Liver Group, Division of Infection, Inflammation and Repair, University of Southampton, Mailpoint 811, Level D South Block, Southampton General Hospital, Tremona Road, Southampton, Hampshire, England, SO16 6YD; fax: (44) 023-8079-6968
  • ,
  • Michael Voelker

      Affiliations

    • Bayer HealthCare AG, Leverkusen, Germany
  • ,
  • Robert Thiel

      Affiliations

    • Thiel Statistical Consultants, Oxford, Connecticut
  • ,
  • Michael Becka

      Affiliations

    • Bayer HealthCare AG, Leverkusen, Germany
  • ,
  • Alastair Burt

      Affiliations

    • School of Clinical and Laboratory Sciences, University of Newcastle Upon Tyne, Newcastle Upon Tyne, England
  • ,
  • Detlef Schuppan

      Affiliations

    • Department of Medicine, University of Erlangen, Erlangen, Germany
  • ,
  • Stefan Hubscher

      Affiliations

    • Department of Pathology, University of Birmingham, Birmingham, England
  • ,
  • Tania Roskams

      Affiliations

    • Department of Pathology, University of Leuven, Leuven, Belgium
  • ,
  • Massimo Pinzani

      Affiliations

    • Department of Medicine, University of Florence, Florence, Italy
  • ,
  • Michael J.P. Arthur

      Affiliations

    • Liver Group, Division of Infection, Inflammation and Repair, University of Southampton, Southampton, England
  • ,
  • European Liver Fibrosis Group

Received 15 December 2003; accepted 19 August 2004.

Background & Aims: Histologic examination of a liver biopsy specimen is regarded as the reference standard for detecting liver fibrosis. Biopsy can be painful and hazardous, and assessment is subjective and prone to sampling error. We developed a panel of sensitive automated immunoassays to detect matrix constituents and mediators of matrix remodeling in serum to evaluate their performance in the detection of liver fibrosis. Methods: In an international multicenter cohort study, serum levels of 9 surrogate markers of liver fibrosis were compared with fibrosis stage in liver biopsy specimens obtained from 1021 subjects with chronic liver disease. Discriminant analysis of a test set of samples was used to identify an algorithm combining age, hyaluronic acid, amino-terminal propeptide of type III collagen, and tissue inhibitor of matrix metalloproteinase 1 that was subsequently evaluated using a validation set of biopsy specimens and serum samples. Results: The algorithm detected fibrosis (sensitivity, 90%) and accurately detected the absence of fibrosis (negative predictive value for significant fibrosis, 92%; area under the curve of a receiver operating characteristic plot, .804; standard error, .02; P < .0001; 95% confidence interval, .758–.851). Performance was excellent for alcoholic liver disease and nonalcoholic fatty liver disease. The algorithm performed equally well in comparison with each of the pathologists. In contrast, pathologists’ agreement over histologic scores ranged from very good to moderate (κ = .97–.46). Conclusions: Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific, and reproducible, suggesting they may be used in conjunction with liver biopsy to assess a range of chronic liver diseases.

Abbreviations used in this paper:  ALD, alcoholic liver disease , AUC, area under the curve , CI, confidence interval , GA, total cohort , GT, test set , GV, validation set , HA, hyaluronic acid , NAFLD, nonalcoholic fatty liver disease , NPV, negative predictive value , PIIINP, N-terminal propeptide of type III collagen , PPV, positive predictive value , ROC, receiver operator characteristic , TIMP-1, tissue inhibitor of matrix metalloproteinase 1

 

 Supported by Bayer Healthcare AG (Leverkusen, Germany). This study is an investigator-initiated study funded by Bayer AG. M.B. and M.V. are employees of Bayer HealthCare AG. R.T. is an independent statistical analyst engaged by Bayer HealthCare AG. A.B., S.H., and T.R. received grant support from Bayer AG.

PII: S0016-5085(04)01553-7

doi:10.1053/j.gastro.2004.08.052

Gastroenterology
Volume 127, Issue 6 , Pages 1704-1713, December 2004